Alfasigma USA, Inc. provides pharmaceuticals focused on improving health and quality of life, particularly targeting an aging population.

Alfasigma USA, Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

Mallinckrodt Pharmaceuticals is a global specialty pharmaceutical company that focuses on advancing the fields of science and medicine to improve lives.

Mallinckrodt Pharmaceuticals

Probitas Partners offers investment advisory services, focused on capital raising for private equity and commercial real estate.

Metric
Company Name	Alfasigma USA, Inc.	AbbVie Inc.	Mallinckrodt Pharmaceuticals	Probitas Partners
Symbol		ABBV
MSH ID	COM:ALFASIGMAUSA	COM:ABBVIE	COM:MALLINCKRODT	COM:PROBITASPARTNERS
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Financial Services & Finance
Industry	Pharmaceuticals	Drug Manufacturers - General	Pharmaceuticals	Investment Management
Country	US	US	IE	US
Stage
Employee Count		50K
Website	alfasigmausa.com	abbvie.com	mallinckrodt.com	probitaspartners.com
LinkedIn
Founders

Metric
Market Cap	296.91B
Enterprise Value
Monthly Web Traffic	1.18M	19.85K
Web Traffic Growth	0.51	-0.79
Valuation
Raised Capital	15B

Metric
Revenue		54.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit		45.54B
EBITDA		18.10B
Operating Income		17.43B
Net Income		4.86B
EPS		2.75
Diluted EPS		2.74
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.72
Operating Profit Margin		0.27
EBITDA Margin		0.33
Net Profit Margin		0.11
Return on Equity		0.57
Return on Assets		0.04
Return on Capital Employed		0.15

COM:ALFASIGMAUSA

Alfasigma USA, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		46.58
P/B Ratio		25.09
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		6.36
EV Multiple		17.44

Metric
Days Sales Outstanding		75.54
Days Payables Outstanding
Days Inventory Outstanding		102.41
Operating Cycle		181.71
Cash Conversion Cycle		179.57
Asset Turnover		0.40

Metric
Operating Cash Flow		22.84B
Free Cash Flow		22.06B
Cash Flow to Debt		0.38
Operating Cash Flow/Sales		0.42
Free Cash Flow Yield		0.08

Metric
Cash & Equivalents		12.81B
Accounts Receivable		66M
Inventory		4.10B
Goodwill		32.29B
Debt to Capitalization		0.91
Debt to Assets		0.45
Current Ratio		0.96
Quick Ratio		0.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.01
R&D to Revenue		0.14
SG&A to Revenue